Terns Pharmaceuticals reports its targeted leukemia drug maintained and even boosted molecular response rates in ...

The ASH meeting included positive early results about a Terns drug for chronic myeloid leukemia and a Kura menin-blocker for ...

While early, study results presented at ASH show Tern’s drug could surpass Novartis’ Scemblix and “raise the bar in efficacy” ...

Terns Pharmaceuticals shares jumped as much as 50% on news that cancer cell counts fell over 99% in nearly three-fourths of ...

Molecular responses continue to deepen with extended treatment duration, reaching 60% major molecular response at 21 cycles ...

Terns Pharmaceuticals (TERN) shares rose 12% on Monday after the company reported additional positive Phase 1 results for its ...

Researchers leading the SWOG S1712 clinical trial have found that adding ruxolitinib to standard tyrosine kinase inhibitor (TKI) treatment for patients with chronic-phase chronic myeloid leukemia ...

Terns Pharmaceuticals reported positive data for its drug designed to treat leukemia, sending shares up. The oncology company said Monday that its treatment TERN-701 showed a 64% major molecular ...

A recent state-of-the-art review highlights that Cardiovascular disease (CVD) and CV risk factors are frequent in patients ...

Dramatically improved disease control with 21.2 months vs. 2.9 months median event-free survival (EFS) Favorablesafety ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. In the years since the approval of Imbruvica for ...

ORLANDO, Fla. - Gleevec, a cancer pill making headlines in recent years because of its remarkable effects against leukemia, may stop the disease from progressing to a deadly stage, doctors said today.